The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
|Videos|May 27, 2020
CMSC 2020 Day 1: Peter Calabresi, MD, on CNS Immune Responses in Progressive MS
Author(s)NeurologyLive® Staff
Peter Calabresi, MD, delivers the Whitaker Lecture as part of the 2020 CMSC Virtual Annual Meeting.
Advertisement
For more coverage from CMSC 2020,
To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020,
To complete the evaluation and claim credit, go to
Advertisement
Related to this article
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
5